It competes with NRF2 for KEAP1 binding and promotes NRF2 activation, which contributes to cell survival, stress resistance, and invasive potential, positioning FAM129B as a potential therapeutic target to control the oxidative stress response and chemoresistance in cancer. Here, NFE2L2 is linked to cancer.